# A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

> **NCT07108894** · PHASE1 · RECRUITING · sponsor: **AbCellera Biologics Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ABCL575
- **BIOLOGICAL:** Placebo (Normal Saline 0.9%)

## Key facts

- **NCT ID:** NCT07108894
- **Lead sponsor:** AbCellera Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108894, "A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07108894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*